Weng-Lang Yang
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$4.3MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $4.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 31, 2018 | NIH | SBIR Phase II Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $487K | THERASOURCE, LLC |
| Apr 18, 2018 | NIH | SBIR Phase II Human Ghrelin as an Effective Mitigator of Acute Radiation Injury | $982K | THERASOURCE, LLC |
| Jul 19, 2017 | NIH | SBIR Phase I A Novel Recombinant Protein as an Effective Therapy for Acute Kidney Injury | $113K | THERASOURCE, LLC |
| Jul 7, 2017 | NIH | SBIR Phase II Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $540K | THERASOURCE, LLC |
| Feb 27, 2017 | NIH | SBIR Phase II Human Ghrelin as an Effective Mitigator of Acute Radiation Injury | $991K | THERASOURCE, LLC |
| Dec 19, 2016 | NIH | SBIR Phase I rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $112K | THERASOURCE, LLC |
| Sep 6, 2016 | NIH | SBIR Phase II Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly | $540K | THERASOURCE, LLC |
| Jan 8, 2016 | NIH | SBIR Phase I rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock | $225K | THERASOURCE, LLC |
| Apr 28, 2015 | NIH | SBIR Phase I A Novel Recombinant Protein for Mitigating Total Body Radiation Injury | $295K | THERASOURCE, LLC |
Peer ranks
Federal funding#348
Awards as PI#151
Patents#273
Companies
- THERASOURCE, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.